Identification of Genomic Biomarkers for Rheumatoid Arthritis With Late Onset

Rheumatoid Arthritis Clinical Trial

— BIOGENOPRAT  

Official title:

Identification of Genomic Biomarkers for Rheumatoid Arthritis With Late Onset

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05808309
• Other study ID #: 2022/0023
• Status: Not yet recruiting
• Start date: September 1, 2024
• Est. completion date: September 1, 2027

Study information

• Verified date: April 2024
• Source: Centre Hospitalier Sud Francilien
• Contact: Pascal HILLIQUIN, MD
• Phone: 01 61 69 31 28
• Email: pascal.hilliquin[@]chsf.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Rheumatoid arthritis (RA) is a disabling disease leading to joint and bones destruction. This autoimmune disease is multifactorial, and some genetic and environmental risk factors are already described. However, a part of heritability is still unknown. Previous genomics studies dedicated to deciphering this missing heritability did not pay attention to age of onset. The purpose of this protocol is to determine genomic markers which are specific of RA with an age of onset above 65 years old. Indeed, clinical presentation, treatment tolerance and efficiency, and frequent comorbidities of this phenotype are particular. This signature of genomic biomarkers will be integrated in known molecular pathways to highlight specificities, helpful for biological targets identification.

Description:

The purpose of this protocol is to identify a genomic signature specific of late onset RA and to contribute to the characterization of dedicated therapeutic targets. Collection of patients will be held at the rheumatology service of CHSF (Corbeil-Essonnes, France) and salivary samples will be collected for further genomic analyses conducted by GenHotel lab (Univ Evry - Univ Paris-Saclay, Evry, France).

First, analysis of whole genome/DNA sequences will allow to identify specific variants of late onset RA. Such identified biomarkers would help differential diagnosis and contribute to earlier initiation of care for RA relatives at risk of developing RA. Second, analysis of RNA sequences, including coding protein genes and non-coding RNA, will give information about gene expression and regulation, and molecular pathways. Comparison of patient groups will allow discrimination of biomarkers and molecular signature specific to the disease and to its onset phenotypes. Integration of such genomic data in the RA disease map (consisted of a network of biological pathways), and further modeling approaches, will highlight late onset RA particularities on which research of therapeutic target could be focused on.

To complete genomic analysis, methylome and proteome data will be produced in a second phase. Such data will help in identification of regulation process leading to a protein profile specific of late onset RA.

An ancillary study is planned from familial samples identified after analysis of data collected from RA patients. Risk genetic markers identification is facilitated in a familial context of analyses. Furthermore, non RA individuals in familial sample provide a control sample allowing better discrimination between family-dependent and phenotype-dependent genomic markers

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: September 1, 2027
• Est. primary completion date: September 1, 2027
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patient with RA diagnosed before 60 years (PRp group)

• patient with RA diagnosed from 65 years (PRt group)

• patient without RA followed for osteoarthritis matched with patient of PRt according to age (+/- 1 year) and sex (Tem group).

• relative of patient PRt, without RA or with RA, regardless of age of onset (Ap group)

• patient who agreed to participate in the study and signed an informed consent

Exclusion Criteria:

• other inflammatory and/or autoimmune known disease for patients of PRp and PRt groups

• first symptoms of osteoarthritis before 40 years, other known inflammatory disease, other known autoimmune disease for Tem group.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Other:
• Salivary sampling
Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)

Locations

Country	Name	City	State
France	Centre Hospitalier Sud Francilien	Corbeil-Essonnes

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Sud Francilien

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Genomic signature for late onset rheumatoid arthritis	Genomic DNA analysis	at day 0
Primary	Gene expression for late onset rheumatoid arthritis	RNA analysis	at day 0
Secondary	Methylome for late onset rheumatoid arthritis	DNA methylation profile	at day 0
Secondary	Proteome for late onset rheumatoid arthritis	Protein profile	at day 0